BioCentury | Oct 24, 2018
Company News

Anaeropharma and Chugai partner to discover cancer drugs using anaerobic bacteria

Anaeropharma Science Inc. (Tokyo, Japan) and Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) partnered to conduct joint research to discover cancer treatments using Anaeropharma's in situ Delivery and Production System (i-DPS) platform. i-DPS modifies anaerobic bacteria Bifidobacterium...
BioCentury | Mar 1, 2018
Targets & Mechanisms

Checking out the microbiome

What started out as a potential use in stratifying patients is growing into a new avenue for turning non-responders to responders, as evidence continues to emerge linking the microbiome to immuno-oncology. While the data are...
BioCentury | Jul 5, 2017
Financial News

Microbiome company Anaeropharma raises $13.2M

Microbiome and cancer play Anaeropharma Science Inc. (Tokyo, Japan) raised $13.2 million from new investors Novartis AG (NYSE:NVS; SIX:NOVN), Shinsei Corporate Investment and Seventure Partners’ Health for Life Capital. Existing investors Innovation Network Corp. of...
BioCentury | Apr 8, 2013
Clinical News

APS001F: Phase I/II started

Anaeropharma began a dose-escalation, U.S. Phase I/II trial to evaluate IV APS001F given on days 1-3 of a 28-day cycle in combination with oral 5-flucytosine in about 75 patients. Anaeropharma Science Inc. , Tokyo, Japan Product:...
BioCentury | Feb 27, 2012
Financial News

Anaeropharma Science proposes venture financing

Anaeropharma Science Inc. , Tokyo, Japan Business: Cancer Date announced: 02/23/12 Type: Venture financing To be raised: Up to ¥2.2 billion ($27.7 million) Investor: Innovation Network Corp. of Japan Note: Anaeropharma said it will raise the...
BioCentury | Feb 25, 2012
Financial News

Anaeropharma to raise up to $27.7 million

Anaeropharma Science Inc. (Tokyo, Japan) said it plans to raise up to Y2.2 billion ($27.7 million) from Innovation Network Corp. of Japan (INCJ). INCJ made an initial Y700 million ($8.8 million) investment in November 2010....
BioCentury | Oct 11, 2010
Company News

Anaeropharma Science, Eisai deal

Eisai received an option to license rights to Anaeropharma's APS001. Eisai received the right of first review of the Phase I results for the recombinant Bifidobacterium longum bacteria that has been modified to expresses the...
Items per page:
1 - 7 of 7